Skip to content

Multicenter randomized controlled clinical trial for therapeutic Evaluation of TCM in patients with extensive small cell lung cancer (SCLC)

Multicenter randomized controlled clinical trial for therapeutic Evaluation of TCM in patients with extensive small cell lung cancer (SCLC)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR1900002318
Enrollment
Unknown
Registered
2019-05-06
Start date
2019-05-13
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

extensive small cell lung cancer

Interventions

The experimental group:traditional chinese medicine treatment combined with chemotherapy
chemoTCM

Sponsors

Beijing Hospital of TCM, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) patients diagnosed with small cell lung cancer by cytology or histology with distant organ metastasis and/or lymph node metastasis of the contralateral hilar lung in extensive stage (via cranial MRI, chest CT, bone scan, abdominal CT or PET/CT); (2) did not receive radiotherapy, chemotherapy or surgical treatment, with evaluable lesions; (3) ECOG score 2, and the expected survival time is > for 3 months; (4) aged 18-75 years, with serious diseases of heart, brain, kidney, liver, blood and other systems; (5) agree to participate in this study and sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) massive pleural or peritoneal effusion or pericardial effusion causes dyspnea; (2) symptomatic bone metastases requiring radiotherapy; (3) brain metastasis; (4) pregnant or lactating women, or serious diseases of heart, lung, liver, kidney, blood and other systems; (5) patients who are known to be allergic to the study drugs; (6) patients undergoing other drug trials.

Design outcomes

Primary

MeasureTime frame
Safety index;OS;

Secondary

MeasureTime frame
TCM syndromes related to lung cancer;PFS;tumor markers;ORR;QOL;

Countries

China

Contacts

Public ContactGuowang Yang

Beijing Hospital of TCM, Capital Medical University

guowangyang@sina.com+86 13701116943

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026